Literature DB >> 27206940

Comparison of different statin therapy to change low-density lipoprotein cholesterol and high-density lipoprotein cholesterol level in Korean patients with and without diabetes.

Ah Reum Khang1, Young Shin Song2, Kyoung Min Kim3, Jae Hoon Moon3, Soo Lim4, Kyong Soo Park2, Hak Chul Jang4, Sung Hee Choi5.   

Abstract

BACKGROUND: It is difficult to apply the proper intensity of statin for new treatment guidelines in clinical settings because of few data about the statin efficacy in Asians. We conducted a retrospective, observational study to estimate the percentage changes in lipid parameters and glucose induced by different statins.
METHODS: We analyzed 3854 patients including those with nondiabetes and diabetes treated at the outpatient clinic between 2003 and 2013 who were statin-naïve and maintained fixed-dose of statin for at least 18 months.
RESULTS: Moderate- and low-intensity statin therapy was effective in reducing low-density lipoprotein cholesterol (LDL-C) to <100 mg/dL (70.3%, 83.0%, and 87.2% of diabetic patients in the low-, moderate-, and high-intensity therapy groups, respectively). The rapid decrease of LDL-C was observed in the first 8 months, and LDL-C-lowering effect was maintained throughout the observation period in even the low-intensity statin group. The effects of statins in elevating high-density lipoprotein cholesterol were similar in each statin groups, except the ezetimibe-simvastatin group (4.5 ± 2.1%) and high-dose atorvastatin groups (9.7 ± 3.3% and 8.7 ± 2.4% for 40 mg and 80 mg of atorvastatin/day, respectively). High-density lipoprotein cholesterol increased less and LDL-C decreased more in diabetes than in nondiabetes. There were no significant changes of fasting glucose after statin use in nondiabetic patients.
CONCLUSIONS: Moderate- or low-intensity statin was effective enough in reaching National Cholesterol Education Program Adult Treatment Panel III LDL-C target goals in Koreans. Low-intensity statin showed around 30% LDL-C reduction from the baseline level in Koreans, which is comparable to moderate-intensity statin in new guideline.
Copyright © 2015 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; Dyslipidemias; HDL; Hydroxy methylglutaryl-CoA reductase inhibitors; LDL; Lipoproteins; Statin efficacy; Triglycerides

Mesh:

Substances:

Year:  2015        PMID: 27206940     DOI: 10.1016/j.jacl.2015.12.013

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  4 in total

1.  Letter: Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2017;41:23-30).

Authors:  Jae Han Jeon
Journal:  Diabetes Metab J       Date:  2017-04       Impact factor: 5.376

2.  Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments.

Authors:  Ye Seul Yang; Seo Young Lee; Jung-Sun Kim; Kyung Mook Choi; Kang Wook Lee; Sang-Chol Lee; Jung Rae Cho; Seung-Jin Oh; Ji-Hyun Kim; Sung Hee Choi
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

Review 3.  High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients.

Authors:  Shiyong Yu; Jun Jin; Zhongxiu Chen; Xiaolu Luo
Journal:  Lipids Health Dis       Date:  2020-08-23       Impact factor: 3.876

4.  Low-density lipoprotein cholesterol : high-density lipoprotein cholesterol ratio is associated with incident diabetes in Chinese adults: A retrospective cohort study.

Authors:  Limin Wei; Meng Wei; Lei Chen; Shanshan Liang; Fanfan Gao; Xin Cheng; Hongli Jiang
Journal:  J Diabetes Investig       Date:  2020-07-07       Impact factor: 4.232

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.